| 1 | [SID103170019] | Active | IC50 | 3.5 | Displacement of [3H]-BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes [AID450269, Type: Literature] | |   View X | Row No. | 1 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Active | | IC50 | 3.5 [uM] | | BioAssay | Displacement of [3H]-BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes | | AID | 450269 | | BioAssay type | Literature | | Target | | | PubMed | 19346132 | | Data Table |  |
|
| 2 | [SID103170019] | Active | IC50 | 3.5 | Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex [AID205267, Type: Literature] | |   View X | Row No. | 2 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Active | | IC50 | 3.5 [uM] | | BioAssay | Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex | | AID | 205267 | | BioAssay type | Literature | | Target | | | PubMed | 2579237 | | Data Table |  |
|
| 3 | [SID48415986] | Active | | | DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other] | |  View X | Row No. | 3 | | Structure |
| | Substance | | | SID | 48415986 | | CID | 37497 | | Outcome | Active | | BioAssay | DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database | | AID | 1195 | | BioAssay type | other | | Target | | | PubMed | | | Data Table |  |
|
| 4 | [SID103170019] | Unspecified | | | Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM [AID205268, Type: Literature] | |   View X | Row No. | 4 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM | | AID | 205268 | | BioAssay type | Literature | | Target | | | PubMed | 2579237 | | Data Table |  |
|
| 5 | [SID103170019] | Unspecified | | | Lethal dose of compound evaluated by administering intraperitoneally to female CRCD mice [AID27367, Type: Literature] | |   View X | Row No. | 5 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Lethal dose of compound evaluated by administering intraperitoneally to female CRCD mice | | AID | 27367 | | BioAssay type | Literature | | Target | | | PubMed | 7288820 | | Data Table |  |
|
| 6 | [SID103170019] | Unspecified | | | Lethal dose of compound evaluated by administering intravenously to female CRCD mice [AID27368, Type: Literature] | |   View X | Row No. | 6 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Lethal dose of compound evaluated by administering intravenously to female CRCD mice | | AID | 27368 | | BioAssay type | Literature | | Target | | | PubMed | 7288820 | | Data Table |  |
|
| 7 | [SID103170019] | Unspecified | | | Anesthetic activity of compound (0.125%) was evaluated by duration of sciatic nerve block [AID174466, Type: Literature] | |   View X | Row No. | 7 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Anesthetic activity of compound (0.125%) was evaluated by duration of sciatic nerve block | | AID | 174466 | | BioAssay type | Literature | | Target | | | PubMed | 7288820 | | Data Table |  |
|
| 8 | [SID103170019] | Unspecified | | | Anesthetic activity of compound (0.25%) was evaluated by duration of sciatic nerve block [AID174596, Type: Literature] | |   View X | Row No. | 8 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Anesthetic activity of compound (0.25%) was evaluated by duration of sciatic nerve block | | AID | 174596 | | BioAssay type | Literature | | Target | | | PubMed | 7288820 | | Data Table |  |
|
| 9 | [SID103170019] | Unspecified | | | Anesthetic activity of compound (0.5%) was evaluated by duration of sciatic nerve block [AID174598, Type: Literature] | |   View X | Row No. | 9 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Anesthetic activity of compound (0.5%) was evaluated by duration of sciatic nerve block | | AID | 174598 | | BioAssay type | Literature | | Target | | | PubMed | 7288820 | | Data Table |  |
|
| 10 | [SID103170019] | Unspecified | | | Lipophilicity, log P of the compound [AID450273, Type: Literature] | |   View X | Row No. | 10 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Lipophilicity, log P of the compound | | AID | 450273 | | BioAssay type | Literature | | Target | | | PubMed | 19346132 | | Data Table |  |
|
| 11 | [SID103170019] | Unspecified | | | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset [AID588220, Type: Literature] | |   View X | Row No. | 11 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Unspecified | | BioAssay | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | | AID | 588220 | | BioAssay type | Literature | | Target | | | PubMed | 20020916 | | Data Table |  |
|
| 12 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 12 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Potentiators: qHTS | | AID | 652051 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 13 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 13 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Potentiators: qHTS | | AID | 652051 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 14 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 14 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Potentiators: qHTS | | AID | 652051 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 15 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 15 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Potentiators: qHTS | | AID | 652051 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 16 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 16 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Agonist: qHTS | | AID | 652048 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 17 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 17 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Agonist: qHTS | | AID | 652048 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 18 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 18 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Agonist: qHTS | | AID | 652048 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 19 | [SID144206521] | Inactive | | | qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening] | DRD3 gene product [Homo sapiens] [gi:89191863] |  View X | Row No. | 19 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | BioAssay | qHTS of D3 Dopamine Receptor Agonist: qHTS | | AID | 652048 | | BioAssay type | screening | | Target | DRD3 gene product [Homo sapiens] [gi:89191863] | | PubMed | | | Data Table |  |
|
| 20 | [SID103170019] | Inactive | | | Inhibition of mouse brain MAOA [AID409954, Type: Literature] | Amine oxidase [flavin-containing] A [gi:341940599] |   View X | Row No. | 20 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Inactive | | BioAssay | Inhibition of mouse brain MAOA | | AID | 409954 | | BioAssay type | Literature | | Target | Amine oxidase [flavin-containing] A [gi:341940599] | | PubMed | 18834112 | | Data Table |  |
|
| 21 | [SID144206521] | Inactive | Potency | | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory] | TDP1 protein [Homo sapiens] [gi:79154014] |  View X | Row No. | 21 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | Potency | [uM] | | BioAssay | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT | | AID | 686979 | | BioAssay type | confirmatory | | Target | TDP1 protein [Homo sapiens] [gi:79154014] | | PubMed | | | Data Table |  |
|
| 22 | [SID144206521] | Inactive | Potency | | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory] | TDP1 protein [Homo sapiens] [gi:79154014] |  View X | Row No. | 22 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | Potency | [uM] | | BioAssay | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT | | AID | 686979 | | BioAssay type | confirmatory | | Target | TDP1 protein [Homo sapiens] [gi:79154014] | | PubMed | | | Data Table |  |
|
| 23 | [SID144206521] | Inactive | Potency | | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory] | TDP1 protein [Homo sapiens] [gi:79154014] |  View X | Row No. | 23 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | Potency | [uM] | | BioAssay | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT | | AID | 686979 | | BioAssay type | confirmatory | | Target | TDP1 protein [Homo sapiens] [gi:79154014] | | PubMed | | | Data Table |  |
|
| 24 | [SID144206521] | Inactive | Potency | | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory] | TDP1 protein [Homo sapiens] [gi:79154014] |  View X | Row No. | 24 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | Potency | [uM] | | BioAssay | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT | | AID | 686978 | | BioAssay type | confirmatory | | Target | TDP1 protein [Homo sapiens] [gi:79154014] | | PubMed | | | Data Table |  |
|
| 25 | [SID144206521] | Inactive | Potency | | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory] | TDP1 protein [Homo sapiens] [gi:79154014] |  View X | Row No. | 25 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | Potency | [uM] | | BioAssay | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT | | AID | 686978 | | BioAssay type | confirmatory | | Target | TDP1 protein [Homo sapiens] [gi:79154014] | | PubMed | | | Data Table |  |
|
| 26 | [SID144206521] | Inactive | Potency | | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory] | TDP1 protein [Homo sapiens] [gi:79154014] |  View X | Row No. | 26 | | Structure |
| | Substance | | | SID | 144206521 | | CID | 37497 | | Outcome | Inactive | | Potency | [uM] | | BioAssay | qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT | | AID | 686978 | | BioAssay type | confirmatory | | Target | TDP1 protein [Homo sapiens] [gi:79154014] | | PubMed | | | Data Table |  |
|
| 27 | [SID103170019] | Inactive | | | Inhibition of mouse brain MAOB [AID409956, Type: Literature] | Amine oxidase [flavin-containing] B [gi:341940629] |   View X | Row No. | 27 | | Structure |
| | Substance | | | SID | 103170019 | | CID | 37497 | | Outcome | Inactive | | BioAssay | Inhibition of mouse brain MAOB | | AID | 409956 | | BioAssay type | Literature | | Target | Amine oxidase [flavin-containing] B [gi:341940629] | | PubMed | 18834112 | | Data Table |  |
|